<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396393</url>
  </required_header>
  <id_info>
    <org_study_id>KY41078-201</org_study_id>
    <nct_id>NCT03396393</nct_id>
  </id_info>
  <brief_title>Exploratory Study of DHA in Systemic Lupus Erythematosus Patients</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of Dihydroartemisinin Tablets in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kunming Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kunming Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy of DHA in patients with SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicentre, randomised, double-blind, placebo-controlled study to
      evaluate the Safety, Pharmacokinetics and Efficacy of four oral treatment regimens of DHA
      versus placebo while taking standard of care (SOC) treatment with corticosteroids in adult
      subjects with Systemic Lupus Erythematosus (SLE).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be received DHA 40mg or DHA 80mg or DHA 120mg or placebo continuously for 24 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SRI,Response at Week 24 according to a combined response index</measure>
    <time_frame>week 24</time_frame>
    <description>The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SLEDAI score</measure>
    <time_frame>week 4,8,12,16,20,24</time_frame>
    <description>Change from baseline in SLEDAI score at week 4,8,12,16,20,24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PAG score</measure>
    <time_frame>week 4,8,12,16,20,24</time_frame>
    <description>Change from baseline in PAG score at week 4,8,12,16,20,24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of daily prednisone dose Less than or equal to 7.5 mg/day</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Number of days of daily prednisone dose Less than or equal to 7.5 mg/day from baseline over 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with UPRO &lt;0.5g/24h</measure>
    <time_frame>Week 4,12,24</time_frame>
    <description>Percent of subjects with UPRO &lt;0.5g/24h from baseline at Week 4,12,24</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Dihydroartemisinin 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dihydroartemisinin 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin tablet</intervention_name>
    <description>DHA tablet</description>
    <arm_group_label>Dihydroartemisinin 40mg</arm_group_label>
    <arm_group_label>Dihydroartemisinin 80mg</arm_group_label>
    <arm_group_label>Dihydroartemisinin 120mg</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Fulfill at least 4 diagnostic criteria for SLE defined by American College of
             Rheumatology;

          2. Positive antinuclear antibodies (ANA);

          3. Activity Index (SLEDAI) score must be 6-11 points, inclusive;

          4. Stable dose of prednisone (&lt;30mg/d) for at least one month ;

          5. Active mild to moderate SLE activity as demonstrated by British Isles Lupus Assessment
             Group Index (BILAG);

          6. Males or females between 18 and 65 years old;

          7. Weight of 45 kg or greater.

        Key Exclusion Criteria:

          1. Active Severe Lupus as defined by BILAG Index Level A or two or more of Level B in any
             body system/organ;

          2. Subjects with concurrent relevant medical conditions like defined chronic infections
             or high risk of new significant infections;

          3. Presence of active central nervous system (CNS) disease requiring treatment;

          4. Subjects with active, severe SLE disease activity which involves the renal system;

          5. Substance abuse or dependence;

          6. History of malignant cancer within the last 5 years;

          7. Subjects with any other condition which, in the investigator's judgment, would make
             the subject unsuitable for inclusion;

          8. Subjects received any live vaccination within the 30 days prior to Visit 2;

          9. Subjects received intravenous immunoglobulin (IVIg) or,plasmapheresis,or High dose
             prednisone or equivalent (&gt; 100 mg/day) within 90 days prior to Visit 2;

         10. Subjects who have had therapy with cyclophosphamide within 180 days prior to Visit 2 .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengchun Zhang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyan Li, Ph.D</last_name>
    <phone>+86-13817688857</phone>
    <email>xinyan.li@holley.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenyu Xu, Ph.D</last_name>
    <phone>+86-10-58611349</phone>
    <email>wenyu.xu@holley.cn</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dihydroartemisinin;Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This study has not been decided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

